On Wednesday, the Apex Court adjourned for 2 weeks hearing on a petition seeking registration of an FIR by the CBI against 10 Indian pharmaceutical firms for manufacturing & selling Remdesivir & Favipiravir, allegedly as medicines to treat Coronavirus patients, without valid licences.
A bench headed by CJI SA Bobde told advocate ML Sharma, who has filed the petition, that there are rules framed by the Indian Govt for the new drugs & clinical trials.
"We are adjourning this matter you see the rule & come back," the bench said while adjourning the matter for 2 weeks.
Remdesivir & Favipiravir are antiviral drugs, however, their efficacy in treating COVID-19 patients has been a matter of debate among medical experts.
The petition claimed that the medicines are being manufactured & sold for treating COVID-19 patients without valid licences from the Central Drugs Standard Control Organisation.
Sharma, through his plea, sought prosecution of the Indian companies for cheating & criminal conspiracy besides under the provisions of the Drug Act, 1940 & said that these medicines have not been certified as medicines for COVID-19 till date by any country.
It said that the companies are manufacturing & selling them at very high rates in India & people are paying that due to the fear of COVID-19 infection & are dying.
It alleged that more than 300 doctors have died in hospitals where these two medicines have been supplied & it amounted to "exploitation of public due to the fear of death."
Source Link
Picture Source :
